Adverse effects of extracorporeal CO2 removal in patients with ards: A single-center retrospective study
Main Article Content
Abstract
This retrospective observational study included 15 patients with acute respiratory distress syndrome (ARDS) treated with extracorporeal carbon dioxide removal (ECCO2R) at the Center for Critical Care Medicine, Bach Mai Hospital, between July 2024 and September 2025. The study aimed to describe ECCO2R-related adverse events and device-associated complications in clinical practice. Hemodynamic parameters, including heart rate and mean arterial pressure, remained stable after ECCO2R initiation, and no patient required vasopressor initiation or dose escalation during ECCO2R support. The median platelet count decreased from 145 G/L prior to ECCO2R to 101 G/L on day 2, whereas hemoglobin concentrations remained stable throughout the treatment period. Filter thrombosis was the most common complication (20%), followed by catheter-site bleeding and hypothermia (6.7% each). No episode of clinically significant bleeding or clinically overt coagulation abnormalities observed. Overall, ECCO2R was hemodynamically well tolerated and was associated with a mild decrease in platelet count, with filter thrombosis being the most frequent device-related complication.
Article Details
Keywords
ECCO2R, ARDS, hemodynamics, hemoglobin, platelets, technical complications
References
2. Sklar MC, Beloncle F, Katsios CM, et al. Extracorporeal carbon dioxide removal in patients with chronic obstructive pulmonary disease: a systematic review. Intensive Care Med. 2015;41(10):1752-1762.
3. Terragni PP, Del Sorbo L, Mascia L, et al. Tidal volume lower than 6 mL/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology. 2009;111(4):826-835.
4. Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy (≈3 mL/kg) combined with extracorporeal CO2 removal versus conventional protective ventilation (6 mL/kg) in severe ARDS: the prospective randomized Xtravent study. Intensive Care Med. 2013;39(5):847-856.
5. Del Sorbo L, Pisani L, Filippini C, et al. Extracorporeal CO2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med. 2015;43(1):120-127.
6. Winiszewski H, Aptel F, Beloncle F, et al. Daily use of extracorporeal CO2 removal in a critical care unit: indications and results. J Intensive Care. 2018;6:36.
7. Smadja DM, Chocron R, et al. Platelet activation and severe bleeding during extracorporeal carbon dioxide removal in chronic obstructive pulmonary disease patients. ASAIO J. 2025;71(2):e20-e22.
8. Matthay MA, Arabi YM, Arroliga AC, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2024;209(1):37-47.
9. Schmidt M, Jaber S, Zogheib E, et al. Feasibility and safety of low-flow extracorporeal CO2 removal managed with a renal replacement platform to enhance lung-protective ventilation in patients with mild-to-moderate ARDS. Crit Care. 2018;22:122.